Edition:
United Kingdom

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

257.10CHF
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
CHF257.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
303,323
52-wk High
CHF270.80
52-wk Low
CHF144.69

Chart for

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 0.99
Market Cap(Mil.): CHF19,317.19
Shares Outstanding(Mil.): 74.47
Dividend: 2.55
Yield (%): 0.98

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Lonza ‍expands offerings for early phase biopharmaceutical drug development​

* Says ‍expands service offerings for early phase biopharmaceutical drug development​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

02 Nov 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

03 Oct 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH, Oct 3 Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

03 Oct 2017

UPDATE 2-Lonza outlines 2022 targets, shares hit record highs

ZURICH, July 26 Swiss pharmaceutical supplier Lonza Group AG set out ambitious growth targets and beat market expectations for first-half core profit, sending its shares more than 6 percent higher on Wednesday.

26 Jul 2017

Lonza confirms 2017 outlook, outlines new 2022 targets

ZURICH, July 26 Swiss pharmaceutical supplier Lonza Group AG on Wednesday confirmed its 2017 outlook and outlined new targets through to 2022.

26 Jul 2017

BRIEF-Lonza H1 sales 15.1 percent up to CHF 2,323 million

* Lonza delivers strong performance in first half 2017 and sets a strong foundation for continued attractive mid-term growth

26 Jul 2017

BRIEF-Lonza says received regulatory approval for Capsugel acquisition

* Says lonza has received all regulatory approvals to move forward with acquisition of Capsugel

27 Jun 2017

Earnings vs. Estimates